Evaluation of Safety and Effectiveness of the EMBLOK EPS During TAVR

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 532 participants.

Also called NCT05295628

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose prevention
Phase
Not applicable
Enrolled
  • 532 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05295628
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT05295628. Randomized; double masking; primary purpose prevention. Start 2023-10-17 (actual); primary completion 2025-05-06 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluation of Safety and Effectiveness of the EMBLOK EPS During TAVR
Condition
Aortic Valve Stenosis
Condition
Aortic Valve Disease
Condition
Aortic Valve Insufficiency
Condition
Aortic Valve Replacement
Intervention (Device)
EMBLOK™ Embolic Protection System ("EMBLOK EPS")
Intervention (Device)
SENTINEL™ Cerebral Protection System
Lead sponsor
Emblok, Inc. (class: industry)
Collaborator
Yale Cardiovascular Research Group (class: other)

Record details

Record id
cardio:ct-nct05295628
Content hash
c2e49a8b351ac8d2b1c97cd5b8b196bba2b2d524d439a85a8105b44f8390e01e